NK cell exhaustion in metastatic melanoma

转移性黑色素瘤中 NK 细胞耗竭

基本信息

  • 批准号:
    9177359
  • 负责人:
  • 金额:
    $ 40.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-27 至 2021-06-30
  • 项目状态:
    已结题

项目摘要

Project summary NK cells are key participants in the initial immune response to tumorigenesis and virus infections, equipped to respond rapidly through induction of cytokines and deployment of cytotoxic activity. A dynamic balance of positive and negative signals regulates NK cell target cell recognition and lysis, through engagement of a variety of activation and inhibitory receptors. However, as cancers advance there is accumulating evidence that NK cells become progressively dysfunctional. NK cell “exhaustion,” could explain the failure of NK cells to contain tumor growth in advanced cancers. While NK cell hyporesponsiveness has been described in various malignancies, there is little characterization of an “exhausted NK cell state” in metastatic disease, nor of the mechanisms that might underlie this phenotype. We now have evidence that NK cells progressively undergo exhaustion in late stage melanoma. Melanoma associated NK cells are characterized by a failure to proliferate, to produce interferon gamma (IFNγ) or to kill target cells. They (i) down regulate activation receptors, IL-2R subunits and NK cell regulatory transcription factors (T-bet, Eomes), (ii) upregulate inhibitory receptors and (iii) express high levels of the checkpoint molecule Tim-3, a phenotype that is consistent with “NK cell exhaustion”. Significantly, blockade of Tim-3 substantially reverses this phenotype and state of exhaustion in vitro (Can. Imm Res. 2014). Most strikingly however, we find that patients who have a clinical response to ipilimumab treatment spontaneously restore their NK cell function, despite the fact that these cells express little or no CTLA-4 (or PD-1 or PD-L1), possibly through reversal of tumor-associated systemic immune suppression. Characterizing NK cell dysfunction in melanoma, therefore, will be critical to understanding the modulation of NK cell biology in the tumor microenvironment (TME), and ultimately towards developing approaches that restore both innate and adaptive immunity, in vivo. Although the survival of advanced melanoma patients (stage IV) has been extended by interventions that reverse T cell exhaustion, we hypothesize that reversal of exhaustion in NK cells will contribute towards the full restoration of immune responses that are required to eliminate melanoma cells. To address this hypothesis, we aim to define the spectrum of NK cell exhaustion in melanoma and identify molecular/protein targets that potentiate NK cell exhaustion (Aim 1). Secondly, we will determine if NK cell exhaustion can be reversed in response to checkpoint blockade inhibition, and identify associated biomarkers (Aim 2). In Aim 3, we will develop murine models to define and test interventions that reverse NK cell exhaustion. Characterizing NK cell dysfunction in melanoma will be critical towards developing approaches that restore immunity, in vivo.
项目总结 NK细胞是肿瘤形成和病毒感染的初始免疫反应的关键参与者, 具备通过诱导细胞因子和部署细胞毒活性进行快速反应的能力。一种动态 正负信号平衡调节NK细胞靶细胞识别和裂解 参与多种激活和抑制受体。然而,随着癌症的发展,有 越来越多的证据表明,NK细胞逐渐功能失调。NK细胞“衰竭”可以解释 晚期癌症患者NK细胞不能抑制肿瘤生长。而NK细胞的低反应性 在不同的恶性肿瘤中都有描述,但很少有人描述在 转移性疾病,也不是这种表型可能的机制。我们现在有证据表明NK 在黑色素瘤晚期,细胞逐渐耗尽。与黑色素瘤相关的NK细胞是 其特征是不能增殖、不能产生干扰素γ或不能杀死靶细胞。他们(I)倒下了 调节激活受体、IL-2R亚单位和NK细胞调节转录因子(T-bet、eome),(Ii) 上调抑制性受体和(Iii)高水平表达检查点分子Tim-3,这是一种表型 与“NK细胞衰竭”相一致。值得注意的是,TIM-3的阻断实质上逆转了这种表型 和体外力竭状态(Can.IMM Res.2014)。然而,最令人惊讶的是,我们发现患有 对ipilimumab治疗的临床反应自发地恢复他们的NK细胞功能,尽管事实是 这些细胞很少表达或不表达CTLA-4(或PD-1或PD-L1),可能是通过逆转与肿瘤相关的 全身免疫抑制。因此,确定黑色素瘤中NK细胞功能障碍的特征对 了解NK细胞生物学在肿瘤微环境(TME)中的调节,并最终走向 开发恢复体内先天免疫和获得性免疫的方法。 尽管通过干预延长了晚期黑色素瘤患者(IV期)的生存期 逆转T细胞衰竭,我们假设NK细胞衰竭的逆转将有助于 完全恢复清除黑色素瘤细胞所需的免疫反应。要解决这个问题 假设,我们的目标是定义黑色素瘤中NK细胞耗竭的光谱并确定分子/蛋白质 增强NK细胞耗竭的靶点(目标1)。其次,我们将确定NK细胞是否可以耗尽 逆转对检查点封锁的抑制,并确定相关的生物标志物(目标2)。在《目标3》中, 我们将开发小鼠模型来定义和测试逆转NK细胞衰竭的干预措施。刻画 黑色素瘤中的NK细胞功能障碍对于开发体内恢复免疫的方法至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nina Bhardwaj其他文献

Nina Bhardwaj的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nina Bhardwaj', 18)}}的其他基金

The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology
蒂施癌症研究所 (TCI) Paul Calabresi K12 临床肿瘤学职业发展奖
  • 批准号:
    10434380
  • 财政年份:
    2022
  • 资助金额:
    $ 40.36万
  • 项目类别:
The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology
蒂施癌症研究所 (TCI) Paul Calabresi K12 临床肿瘤学职业发展奖
  • 批准号:
    10623252
  • 财政年份:
    2022
  • 资助金额:
    $ 40.36万
  • 项目类别:
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer
剖析膀胱癌中骨髓细胞介导的免疫检查点阻断抵抗
  • 批准号:
    10652272
  • 财政年份:
    2020
  • 资助金额:
    $ 40.36万
  • 项目类别:
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer
剖析膀胱癌中骨髓细胞介导的免疫检查点阻断抵抗
  • 批准号:
    10380068
  • 财政年份:
    2020
  • 资助金额:
    $ 40.36万
  • 项目类别:
Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy
SARS-CoV-2 对接受免疫治疗的患者临床病程和 NK 细胞的影响
  • 批准号:
    10203557
  • 财政年份:
    2020
  • 资助金额:
    $ 40.36万
  • 项目类别:
Cancer Immunology
癌症免疫学
  • 批准号:
    10454170
  • 财政年份:
    2015
  • 资助金额:
    $ 40.36万
  • 项目类别:
Cancer Immunology (CI) (Project-001)
癌症免疫学 (CI)(项目-001)
  • 批准号:
    8932191
  • 财政年份:
    2015
  • 资助金额:
    $ 40.36万
  • 项目类别:
Cancer Immunology
癌症免疫学
  • 批准号:
    10674510
  • 财政年份:
    2015
  • 资助金额:
    $ 40.36万
  • 项目类别:
Cancer Immunology
癌症免疫学
  • 批准号:
    10022663
  • 财政年份:
    2015
  • 资助金额:
    $ 40.36万
  • 项目类别:
Matrix metalloproteinase-2 modulates inflammation via TLR2
基质金属蛋白酶-2 通过 TLR2 调节炎症
  • 批准号:
    8777819
  • 财政年份:
    2014
  • 资助金额:
    $ 40.36万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 40.36万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 40.36万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 40.36万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 40.36万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 40.36万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 40.36万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 40.36万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 40.36万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 40.36万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 40.36万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了